Re: Faisal S. BinHumaid, Anshita Goel, Naheema S. Gordon, et al. Circulating Tumour DNA Positivity Predicts Shorter Survival for Patients with High-grade pT1 Urothelial Bladder Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.11.007 [0.03%]
高分级pT1膀胱尿路上皮癌患者循环肿瘤DNA阳性预示生存期较短：Eur Urol待刊论文
Pierre-Etienne Gabriel,John P Sfakianos,Evanguelos Xylinas
Pierre-Etienne Gabriel
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group [0.03%]
肌层浸润性膀胱癌的规范管理：国际膀胱癌组的建议
Shilpa Gupta,Roger Li,Patrick J Hensley et al.
Shilpa Gupta et al.
Background and objective: The management of muscle-invasive bladder cancer (MIBC) is evolving rapidly with the emergence of new perioperative treatments and approaches for bladder preservation. We provide guidance on clin...
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study [0.03%]
IMPACT研究：BRCA1/2基因突变携带者的前列腺癌针对性筛查发现具有临床意义的癌症：5年期结果报告
Elizabeth K Bancroft,Elizabeth C Page,Jana McHugh et al.
Elizabeth K Bancroft et al.
Background and objective: BRCA1 and BRCA2 pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (PC). The IMPACT study evaluated the utility of targeted prostate-specific antigen (PSA) scr...
Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)] [0.03%]
“针对未接受过卡介杆菌免疫治疗的高危非肌层浸润性膀胱癌患者，检查点抑制剂联合卡介苗(BCG)与单纯使用BCG疗效和安全性的比较：ALBAN、CREST 和 POTOMAC 试验结果综合分析”的勘误 [ Eur. Urol. (2025)]
Pietro Scilipoti,Paolo Zaurito,Mattia Longoni et al.
Pietro Scilipoti et al.
Published Erratum
European urology. 2026 Feb 17:S0302-2838(26)00063-1. DOI:10.1016/j.eururo.2026.02.001 2026
Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis [0.03%]
双参数磁共振成像与多参数磁共振成像在诊断前列腺癌中的诊断性能：一项系统综述和荟萃分析更新
Guilherme Strieder de Oliveira,Stephan Altmayer,Giovanni Brondani Torri et al.
Guilherme Strieder de Oliveira et al.
Background and objective: Multiparametric magnetic resonance imaging (mpMRI) is the reference modality for detecting clinically significant prostate cancer (csPC). Biparametric MRI (bpMRI), which omits contrast, has emerg...
Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy for Localized Prostate Cancer. A Meta-analysis [0.03%]
根治性放疗联合雄激素剥夺治疗前列腺癌的最佳疗程：一项系统综述和meta分析
Alessandro Viti,Simone Scuderi,Alberto Briganti et al.
Alessandro Viti et al.
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide [0.03%]
FORMULA-509：术后放疗联合6个月的 GnRH 激动剂、比卡鲁胺或醋酸阿比特龙+泼尼松或阿帕他胺治疗去势抵抗性生化复发前列腺癌的多中心随机3期临床试验
Paul L Nguyen,Marisa A Kollmeier,Dana E Rathkopf et al.
Paul L Nguyen et al.
Background and objective: For patients with detectable prostate-specific antigen (PSA) after radical prostatectomy, 6 mo of a GNRH agonist with salvage radiotherapy (sRT) is a standard treatment option. ...
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer [0.03%]
恩扎卢胺治疗生化复发前列腺癌患者的生存改善反应分析
Francesco Barletta,Chiara Mercinelli,Francesco Montorsi et al.
Francesco Barletta et al.